Filing Flows

Filing Flows › Companies › Stoke Therapeutics › Cash flow

Stoke Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$65.5M in Q3 2026 · −$216M over twelve months

Operating cash flow−$62.7M
Capital spending−$2.9M
Free cash flow−$65.5M

Analysis

In Q3 2026, Stoke Therapeutics generated −$62.7M of operating cash flow and spent $2.9M on capital projects, leaving free cash flow of −$65.5M. That is $35.0M less than in Q3 2025 (−$30.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$210M; the largest uses were operating cash flow ($210M), other investing ($6.1M), capital spending ($5.4M); besides operations, cash came from other financing ($236M), shares issued ($13.2M); the cash balance rose by $26.9M.

Operating cash flow was −$62.7M against net income of −$73.6M. The largest differences: stock-based pay +$11.0M, prepaid and other assets −$4.1M, deferred revenue −$3.4M.

Free cash flow

Stoke Therapeutics: free cash flow by quarterStoke Therapeutics: free cash flow by quarter−$23.2MQ4 2024$132MQ1 2025−$25.6MQ2 2025−$30.5MQ3 2025−$30.7MQ4 2025−$60.9MQ1 2026−$58.6MQ2 2026−$65.5MQ3 2026
Operating cash flow less capital spending.
Stoke Therapeutics: operating cash flow against capital spendingStoke Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$23.2M$42KQ4 2024$132M$152KQ1 2025−$25.4M$154KQ2 2025−$30.4M$132KQ3 2025−$30.5M$232KQ4 2025−$60.6M$353KQ1 2026−$56.6M$2.0MQ2 2026−$62.7M$2.9MQ3 2026
Latest (Q3 2026): Operating cash flow −$62.7M, Capital spending $2.9M.

Capital allocation, year by year

Stoke Therapeutics: where the cash came from (up) and went (down), by fiscal yearStoke Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$66.9MFY2021: Shares issued $777KFY2021: Capital spending −$1.2M$777KFY2021FY2022: Operating cash flow −$31.9MFY2022: Shares issued $494KFY2022: Capital spending −$4.0M$494KFY2022FY2023: Operating cash flow −$81.1MFY2023: Shares issued $371KFY2023: Capital spending −$1.6M$371KFY2023FY2024: Operating cash flow −$86.9MFY2024: Shares issued $1.7MFY2024: Capital spending −$203K$1.7MFY2024FY2025: Operating cash flow $45.6MFY2025: Shares issued $8.6MFY2025: Capital spending −$670K$54.2MFY2025
Over these 5 years operating cash flow totalled −$221M; the largest uses were operating cash flow ($267M) and capital spending ($7.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$319M
Debtnone
Net cash$319M
Cash runway18 months

Stoke Therapeutics is burning cash: its operations consume cash, a free cash flow of −$216M a year at the current rate against $319M of cash and investments: a runway of about 18 months before any new financing.

Where the cash came from and went

Stoke Therapeutics: sources (+) and uses (−) of cash, Q3 2026Stoke Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other financing$66.6MOperating cash flow−$62.7MOther investing−$7.4MShares issued$3.5MCapital spending−$2.9MCash drawn (+) / kept (−)$2.7M
Stoke Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Stoke Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$236MOperating cash flow−$210MCash drawn (+) / kept (−)−$26.9MShares issued$13.2MOther investing−$6.1MCapital spending−$5.4M

From profit to cash

Stoke Therapeutics: net income to operating cash flow, Q3 2026Stoke Therapeutics: net income to operating cash flow, Q3 2026Net income−$73.6MDepreciation & amortization$455KStock-based pay$11.0MReceivables−$1.4MDeferred revenue−$3.4MPrepaid and other assets−$4.1MOperating cash flow−$62.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$62.7M−$2.9M$3.5M$2.7M−$65.5M
Q2 2026−$56.6M−$2.0M$1.9M$45.7M−$58.6M
Q1 2026−$60.6M−$353K$3.2M−$74.4M−$60.9M
Q4 2025−$30.5M−$232K$4.6M−$826K−$30.7M
Q3 2025−$30.4M−$132K$2.5M$18.2M−$30.5M
Q2 2025−$25.4M−$154K$554K$173M−$25.6M
Q1 2025$132M−$152K$1.0M−$147M$132M
Q4 2024−$23.2M−$42K$567K$21.8M−$23.2M

Stoke Therapeutics: income statement and cash flow

Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%. The chart follows the revenue to costs, profit and cash.

Stoke Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.